SCHEMBL24499467

SCHEMBL24499467

O=S(=O)(c1cncc(Br)c1)N1CCOc2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.55
POLB P06746 1/20 0.47
NAMPT P43490 1/20 0.47
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 2/20 0.44
NR1H3 Q13133 2/20 0.44
MAPT P10636 1/20 0.42
JAK2 O60674 2/20 0.41
PKM P14618 2/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
RORC P51449 2/20 0.40
HTR6 P50406 2/20 0.40
CYP2C9 P11712 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
NR1H2 P55055 1/20 0.39
RXFP1 Q9HBX9 1/20 0.37
NOTUM Q6P988 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29598196 0.81 NPC1 (0.50) NPC1POLBNAMPTMEN1KMT2A
SCHEMBL24499511 0.81 NPC1 (0.50) NPC1POLBNAMPTMEN1KMT2A
SCHEMBL5470927 0.77 ALDH1A1 (0.62) MEN1KMT2AALDH1A1JAK2PKM
SCHEMBL2995685 0.76 NPC1 (0.58) NPC1POLBNAMPTMEN1KMT2A
SCHEMBL1633443 0.74 NPC1 (0.53) NPC1POLBMEN1KMT2AALDH1A1
SCHEMBL16217090 0.74 NPC1 (0.74) NPC1POLBNAMPTMEN1KMT2A
SCHEMBL25754848 0.73 NPC1 (0.62) NPC1POLBMEN1KMT2AALDH1A1
SCHEMBL31750670 0.73 NPC1 (0.62) NPC1POLBMEN1KMT2AALDH1A1
SCHEMBL4901779 0.72 NPC1 (0.57) NPC1POLBNAMPTMEN1KMT2A
SCHEMBL25166791 0.72 NPC1 (0.67) NPC1POLBNAMPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022117920-A1 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHENYL)-PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP11A1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER ORION CORPORATION (FI) 2022-06-09 WO disclosed